CD89 Antibody, anti-human, REAfinity™
Synonyms: FCAR, CTB-61M7.2, FcαRI
RECOMBINANT EXTENDED VALIDATION
Bioz Star90/100 Bioz rating
1 Citation
Clone:
REA234 | MIP8a
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC, FA Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD89 Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
FITC
PE
PE-Vio 770
PerCP-Vio 700
Vio Bright R720
Vio Bright V423
Recommended dilution:
1:11
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-101-383, 130-101-384
Description:
Human peripheral blood cells after erythrocyte lysis were stained with CD89 antibodies as well as with CD16 antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application image
MICS (MACSima Imaging Cyclic Staining) applications
APC
FITC
PE
Fixation:
frozen – PFA
Species tested:
human
Recommended dilution:
1:11
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-101-383, 130-101-384
Testing grade:
Functional assay applications
pure-functional grade
Type of functional assay:
blocking of receptor-ligand binding
Conjugate:
pure-functional grade
Used products:
130-101-089
Extended validation for CD89 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA234
A59
low
MIP8a
partial

Cells were incubated with an excess of purified unconjugated CD89 (REA234) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD89. Human peripheral blood mononuclear cells (PBMCs) after erythrocyte lysis were stained with CD89antibodies and with a suitable counterstaining. As a control, CD89 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD89 shown as histograms

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD89 (REA234). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD89 Antibody, anti-human, REAfinity™
Overview

Clone REA234 recognizes CD89, the human myeloid IgA Fc receptor. CD89 is a glycosylated transmembrane protein that binds both IgA subclasses (IgA1 and IgA2) and is closely related to the KIR and MIR proteins rather than to other human Fc receptors. CD89 itself lacks the canonical signal transduction domains, however it associates with the FcR γ-chain with an immunoreceptor tyrosine-based activation (ITAM) motif, which allows transduction of activation signal upon ligand binding. FcαRI alone mediates endocytosis and recyling of IgA. Expression of CD89 is found on neutrophils, eosinophils, monocytes/macrophages, dendritic cells, and Kupffer cells.

Additional information: Clone REA234 displays negligible binding to Fc receptors.

Alternative names

FCAR, CTB-61M7.2, FcαRI

Detailed product information

Technical specifications

Clone
REA234
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD89
Distribution of antigen
dendritic cells, macrophages, monocytes, eosinophils
Entrez Gene ID
RRID
AB_2921843, AB_2921943, AB_2905140, AB_2928577, AB_2921824, AB_2659468, AB_2659466, AB_2928578, AB_2905139, AB_2659469, AB_2659458, AB_2659467, AB_2921963, AB_2659463, AB_2659470, AB_2659464, AB_2659465

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD89 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?